معرفی
Dr. Xinsheng Ju is a Senior Research Fellow at the ANZAC Research Institute under the Faculty of Medicine and Health at the University of Sydney. His research focuses on immunology, particularly the regulation of dendritic cells and immune cell functions via molecules like CD300 and CD83. Key areas include cancer immunotherapy, autoimmune disease modulation, and transplantation immunology.
Research interests center on understanding immune cell activation markers (e.g., CD83), dendritic cell subpopulations, and therapeutic applications of monoclonal antibodies targeting these markers. Notable contributions include studies on CD83 as a biomarker for lymphoma and its role in immunosuppression during transplantation.
Publications span over 20 years, emphasizing CD300 signaling in dendritic cells, CD1c+ myeloid cell function, and novel vaccine strategies for prostate cancer. His work bridges basic immunology with clinical translation, particularly in oncology and transplant medicine.
Collaborations include studies on antibody-based therapies for arthritis and lymphoma, leveraging preclinical models and humanized systems. The lab's focus remains on identifying therapeutic targets and immune regulatory pathways critical to disease intervention.
